Akari Therapeutics PLC (AKTX)

[Rogerthat1]

Luckily for Alexion, Brazil is a small market but this could result in similar situations in other areas where Alexion has a strong hold. Ceo of aktx has repeatedly made comments about Akari intending to undercut Alexion on pricing so this bodes well for aktx imo. Below remarks from most recent ER call.

Yes, another good question. I won't comment too much, it's Alexion's product and for them to discuss in more detail but obviously for those following their studies it was done non-inferior, their conclusion was non-inferior to Soliris and our result at 45 milligrams today is approximately equivalent to Soliris in terms of both approximate LDH numbers but most importantly reduction of transfusions and so you know 1210 is a good idea because it's less frequent dosing but it's still IV infusion and ours is subcu and we think ultimately the differentiation of subcu dosing in patient self-control is very important for patients. I think ours is a very, very good medicine in terms of reduction of transfusions on the other hand and I think the other you know important feature is that we have not yet formally addressed but we look forward to addressing is pricing, we know that the pricing is stable for Alexion and we think that there is room to discuss that pricing as we move forward.

$AKTX